PDCD1 and non-small cell lung carcinoma: In a Phase 1 clinical study, Enoblituzumab was evaluated in combination with an anti-PD-1 mAb in patients (n=133) with B7-H3-expressing melanoma, HNSCC, NSCLC and UC.